The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo

被引:137
作者
Hermans, IF [1 ]
Silk, JD
Yang, JP
Palmowski, MJ
Gileadi, U
McCarthy, C
Salio, M
Ronchese, F
Cerundolo, V
机构
[1] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Nuffield Dept Med,Tumour Immunol Unit, Oxford OX3 9DS, England
[2] Wellington Sch Med, Malaghan Inst Med Res, Wellington, New Zealand
关键词
cytotoxic T lymphocytes; NKT cells; flow cytometry; cytotoxicity assay; CFSE; CMTMR;
D O I
10.1016/j.jim.2003.10.017
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Assessment of cell-mediated toxicity has traditionally been achieved by measuring the specific activity of enriched effector cell populations against antigen-loaded target cells labeled with radioactive isotopes in vitro. Fluorometric techniques are viewed as a promising alternative to the use of radioactive isotopes for these analyses. Direct assessment of cytotoxicity in vivo can be achieved by monitoring survival of injected fluorescent targets relative to a differentially labeled internal control population without specific antigen. We have developed this approach, incorporating the use of multiple target cell populations labeled with different dyes so that cytotoxicity can be assessed against titrated doses of a given antigen, or against a range of different antigens, simultaneously. We show that this assay, referred to as the VITAL assay, can be used to assess cytotoxic activity of CTL and iNKT cells in vivo and in vitro. CTL responses measured in vivo could be correlated with antigen doses used in immunization strategies, and also with the size of specific CTL populations enumerated in the blood with fluorescent MHC/peptide tetramers. The VITAL assay is, therefore, a sensitive technique allowing analysis of complex multi-epitope responses. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:25 / 40
页数:16
相关论文
共 48 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]  
Aubry JP, 1999, CYTOMETRY, V37, P197, DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO
[3]  
2-L
[4]  
Barchet W, 2000, EUR J IMMUNOL, V30, P1356, DOI 10.1002/(SICI)1521-4141(200005)30:5<1356::AID-IMMU1356>3.0.CO
[5]  
2-K
[6]   In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers [J].
Benlagha, K ;
Weiss, A ;
Beavis, A ;
Teyton, L ;
Bendelac, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (11) :1895-1903
[7]  
BRUNNER KT, 1968, IMMUNOLOGY, V14, P181
[8]   Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL [J].
Chen, JL ;
Dunbar, PR ;
Gileadi, U ;
Jäger, E ;
Gnjatic, S ;
Nagata, Y ;
Stockert, E ;
Panicalli, DL ;
Chen, YT ;
Knuth, A ;
Old, LJ ;
Cerundolo, V .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :948-955
[9]   Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes [J].
Crawford, F ;
Kozono, H ;
White, J ;
Marrack, P ;
Kappler, J .
IMMUNITY, 1998, 8 (06) :675-682
[10]   Requirement for V(alpha)14 NKT cells in IL-12-mediated rejection of tumors [J].
Cui, JQ ;
Shin, T ;
Kawano, T ;
Sato, H ;
Kondo, E ;
Toura, I ;
Kaneko, Y ;
Koseki, H ;
Kanno, M ;
Taniguchi, M .
SCIENCE, 1997, 278 (5343) :1623-1626